{"doi":"10.1093/cid/ciz1034","title":"Comparative Immunogenicity of Several Enhanced Influenza Vaccine Options for Older Adults: A Randomized, Controlled Trial","abstract":"

Background

Enhanced influenza vaccines may improve protection for older adults, but comparative immunogenicity data are limited. Our objective was to examine immune responses to enhanced influenza vaccines, compared to standard-dose vaccines, in community-dwelling older adults.

Methods

Community-dwelling older adults aged 65-82 years in Hong Kong were randomly allocated (October 2017-January 2018) to receive 2017-2018 Northern hemisphere formulations of a standard-dose quadrivalent vaccine, MF59-adjuvanted trivalent vaccine, high-dose trivalent vaccine, or recombinant-hemagglutinin (rHA) quadrivalent vaccine. Sera collected from 200 recipients of each vaccine before and at 30-days postvaccination were assessed for antibodies to egg-propagated vaccine strains by hemagglutination inhibition (HAI) and to cell-propagated A/Hong Kong/4801/2014(H3N2) virus by microneutralization (MN). Influenza-specific CD4+ and CD8+ T cell responses were assessed in 20 participants per group.

Results

Mean fold rises (MFR) in HAI titers to egg-propagated A(H1N1) and A(H3N2) and the MFR in MN to cell-propagated A(H3N2) were statistically significantly higher in the enhanced vaccine groups, compared to the standard-dose vaccine. The MFR in MN to cell-propagated A(H3N2) was highest among rHA recipients (4.7), followed by high-dose (3.4) and MF59-adjuvanted (2.9) recipients, compared to standard-dose recipients (2.3). Similarly, the ratio of postvaccination MN titers among rHA recipients to cell-propagated A(H3N2) recipients was 2.57-fold higher than the standard-dose vaccine, which was statistically higher than the high-dose (1.33-fold) and MF59-adjuvanted (1.43-fold) recipient ratios. Enhanced vaccines also resulted in the boosting of T-cell responses.

Conclusions

In this head-to-head comparison, older adults receiving enhanced vaccines showed improved humoral and cell-mediated immune responses, compared to standard-dose vaccine recipients.

Clinical trials registration

NCT03330132.","journal":"Clinical Infectious Diseases","year":2019,"id":737,"datarank":6.0163284958757615,"base_score":4.7535901911063645,"endowment":4.7535901911063645,"self_citation_contribution":0.7130385286659547,"citation_network_contribution":5.303289967209807,"self_endowment_contribution":0.7130385286659547,"citer_contribution":5.303289967209807,"corpus_percentile":null,"corpus_rank":null,"citation_count":115,"citer_count":90,"citers_with_citation_signal":74,"citers_with_endowment":74,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.1809,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2019-12-12","algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":7165,"name":"Ranawaka A. P. M. Perera","orcid":"0000-0003-3936-1535","position":1,"is_corresponding":false},{"id":7166,"name":"Sophie A. Valkenburg","orcid":"0000-0002-0768-9926","position":2,"is_corresponding":false},{"id":7167,"name":"Nancy H L Leung","orcid":null,"position":3,"is_corresponding":false},{"id":7168,"name":"A. Danielle Iuliano","orcid":"0000-0001-8742-3687","position":4,"is_corresponding":false},{"id":7169,"name":"Yat Hung Tam","orcid":null,"position":5,"is_corresponding":false},{"id":7170,"name":"Jennifer H F Wong","orcid":null,"position":6,"is_corresponding":false},{"id":7171,"name":"Vicky J. Fang","orcid":"0000-0002-3741-910X","position":7,"is_corresponding":false},{"id":7172,"name":"Athena P. Y. Li","orcid":null,"position":8,"is_corresponding":false},{"id":7173,"name":"Hau Chi So","orcid":"0000-0003-3119-1527","position":9,"is_corresponding":false},{"id":7174,"name":"Dennis K M Ip","orcid":null,"position":10,"is_corresponding":false},{"id":7175,"name":"Eduardo Azziz-Baumgartner","orcid":null,"position":11,"is_corresponding":false},{"id":7176,"name":"Alicia M. Fry","orcid":"0000-0002-3208-9308","position":12,"is_corresponding":false},{"id":7177,"name":"Min Z. Levine","orcid":"0000-0002-3197-1649","position":13,"is_corresponding":false},{"id":7178,"name":"Shivaprakash Gangappa","orcid":"0000-0001-6217-9665","position":14,"is_corresponding":false},{"id":7179,"name":"Suryaprakash Sambhara","orcid":"0000-0002-4715-5793","position":15,"is_corresponding":false},{"id":7180,"name":"Ian G Barr","orcid":null,"position":16,"is_corresponding":false},{"id":7181,"name":"Danuta M. Skowronski","orcid":"0000-0001-5870-6733","position":17,"is_corresponding":false},{"id":7182,"name":"J S Malik Peiris","orcid":null,"position":18,"is_corresponding":false},{"id":7183,"name":"Mark G. Thompson","orcid":"0000-0003-0046-3147","position":19,"is_corresponding":false},{"id":7184,"name":"Nancy Leung","orcid":"0000-0001-7314-840X","position":20,"is_corresponding":false},{"id":7185,"name":"Dkm Ip","orcid":"0000-0003-3592-8709","position":21,"is_corresponding":false},{"id":7186,"name":"Eduardo Azziz‐Baumgartner","orcid":"0000-0001-8038-0530","position":22,"is_corresponding":false},{"id":7187,"name":"Ian Barr","orcid":"0000-0002-7351-418X","position":23,"is_corresponding":false},{"id":7188,"name":"Malik Peiris","orcid":"0000-0001-8217-5995","position":24,"is_corresponding":false},{"id":7164,"name":"Benjamin J. Cowling","orcid":"0000-0002-6297-7154","position":0,"is_corresponding":true}],"reference_count":27,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-03-01T18:20:47.508186Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}